GlobeNewswire

AGF Completes Acquisition of 100% of FFCM

Dela

Strategic investment supports diversification and growth of quantitative platform 

BOSTON and TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- AGF Management Limited (TSX:AGF.B) today announced it successfully completed its acquisition of 100% of FFCM, LLC (FFCM) earlier this month to further strengthen their quantitative investing and ETF platform brought to market under the AGFiQ banner.

"Today, we further build on our strategic plan to diversify across the investment spectrum," said Judy Goldring, Executive Vice-President and Chief Operating Officer, AGF. "Through organic growth and acquisition we have been able to launch new platforms and develop innovative products."

In November 2015, AGF acquired the majority of the equity of FFCM, a Boston-based boutique asset manager and ETF strategist whose expertise is delivered through a family of factor-based alternative and smart-beta ETFs and a number of ETF managed solutions.

The acquisition resulted in the launch of AGFiQ Asset Management (AGFiQ), a quantitative investment platform powered by the intellectually diverse, multi-disciplined team that combines the complementary strengths of investment professionals from AGF, Highstreet Asset Management (Highstreet) - which became a part of the AGF family through an acquisition in 2006 - and FFCM.

AGFiQ came to market as a combined platform in late 2017 and has since delivered nine ETFs to the Canadian marketplace and secured over $US 400 million in institutional funding for an AGFiQ custom solution in the United States over the last three months.

"We had the foresight to see that by combining the research acumen, investment capabilities and intellectual capital of Highstreet and FFCM we could effectively expand our presence in the quantitative investment space," added Goldring.

"This is a natural next step in our partnership and reinforces that we are a part of the AGF family," said Bill Carey, Chief Executive Officer, FFCM. "Partnering with AGF has allowed us to grow our research, marketing and product development capabilities, while also bringing us operational scale and efficiencies."

"This acquisition supports the long-term diversification of our investment capabilities allowing us to deliver value-added and differentiated opportunities within our yield, global and quantitative platforms to provide our global client base with the outcomes they seek," said Kevin McCreadie, President and Chief Investment Officer, AGF Investments Inc.   

About AGF Management Limited 
Founded in 1957, AGF Management Limited (AGF) is a diversified global asset management firm with retail, institutional, alternative and high-net-worth businesses. As an independent firm, AGF brings a disciplined approach to delivering excellence in investment management and providing an exceptional client experience. AGF's suite of diverse investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.

AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With $37 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

About AGFiQ Asset Management

AGFiQ Asset Management is the quantitative investment platform for AGF powered by an intellectually diverse, multi-disciplined team that combines the complementary strengths Highstreet Asset Management Inc. (Highstreet), located in London, Ontario and FFCM, LLC (FFCM), located in Boston, and are supported by a team of 20 investment professionals from across AGF and its affiliates, managing AUM of approximately C$5.7 billion. AGFiQ's portfolio and investment management team has extensive experience in quantitative investing and research with a core investment discipline focused on factor-based investing. AGFiQ is grounded in the belief that investment outcomes can be improved by assessing and targeting the factors that drive market returns. 

Media Contact

Amanda Marchment
Director, Corporate Communications
416-865-4160
amanda.marchment@agf.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AGF Management Ltd. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum